Investigating how immune cells contribute to brain damage in inflammatory diseases
Enabled by drug delivery: Studying the role of brain-resident and infiltrating myeloid cell phenotype in brain damage associated with inflammatory disease
This study is looking at how certain immune cells can cause brain damage after injuries or autoimmune diseases, and it's for anyone interested in finding better treatments for brain injuries by using new ways to target these immune cells.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Oklahoma NIH-funded |
| Lab location | 1 site (Norman, United States) |
| Project ID | NIH-10894057 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of immune cells in causing acute brain damage due to conditions like traumatic injuries and autoimmune diseases. Researchers are exploring how activated immune cells from the bloodstream and resident brain cells interact and contribute to inflammation and brain injury. They are using innovative drug delivery technologies to target these immune cells and assess their impact on brain health. The goal is to fill knowledge gaps that could lead to better treatments for patients suffering from brain injuries.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who have experienced traumatic brain injuries, autoimmune diseases, or other conditions leading to acute brain inflammation.
Not a fit: Patients with chronic, non-inflammatory neurological conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that better manage or prevent brain damage in patients with inflammatory diseases.
How similar studies have performed: Previous research has shown promise in understanding immune cell roles in brain injury, but this approach using novel drug delivery methods is relatively new.
Where this research is happening
Norman, United States
- University of Oklahoma — Norman, United States (Active)
Researchers
- Principal investigator: Clegg, John R — University of Oklahoma
- Study coordinator: Clegg, John R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.